BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhao Q, Chen Y, Du S, Yang X, Chen Y, Ji Y, Zeng Z. Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases. Cancer Biol Ther 2021;22:175-83. [PMID: 33722163 DOI: 10.1080/15384047.2020.1834792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Song J, Di Y, Kang X, Ren G, Wang Y. Development and validation of a nomogram to predict cancer-specific survival with unresected cholangiocarcinoma undergoing external radiotherapy. Front Public Health 2023;11. [DOI: 10.3389/fpubh.2023.1012069] [Reference Citation Analysis]
2 Jiang J, Diaz DA, Nuguru SP, Mittra A, Manne A. Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. Cancers (Basel) 2022;15. [PMID: 36612046 DOI: 10.3390/cancers15010050] [Reference Citation Analysis]
3 Wang N, Huang A, Kuang B, Xiao Y, Xiao Y, Ma H. Progress in Radiotherapy for Cholangiocarcinoma. Front Oncol 2022;12:868034. [DOI: 10.3389/fonc.2022.868034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]